Compounds > 2'-cyano-2'-deoxyarabinofuranosylcytosine
Page last updated: 2024-12-07

2'-cyano-2'-deoxyarabinofuranosylcytosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

2'-cyano-2'-deoxyarabinofuranosylcytosine: structure given in first source; RN given is for mono HCl [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3035200
CHEMBL ID1204346
MeSH IDM0191444

Synonyms (25)

Synonym
CHEMBL1204346
134665-72-8
2'-cyano-2'deoxy-1-beta-d-arabinofuranosylcytosine
2'-cyano-2'-deoxyarabinofuranosylcytosine
4-amino-1-(2-cyano-2-deoxy-beta-d-arabinofuranosyl)-2(1h)-pyrimidinone monohydrochloride
unii-vss4zdz2ie
2(1h)-pyrimidinone, 4-amino-1-(2-cyano-2-deoxy-beta-d-arabinofuranosyl)-, monohydrochloride
vss4zdz2ie ,
DTXSID30158861
2/'-cyano-2/'-deoxyarabinofuranosylcytosine
cndac hydrochloride
AKOS030627139
2'-cyano-2'-deoxy-1-(.beta.-d-arabinofuranosyl)cytosine monohydrochloride
2(1h)-pyrimidinone, 4-amino-1-(2-cyano-2-deoxy-.beta.-d-arabinofuranosyl)-, monohydrochloride
tas-109 hydrochloride
cndac monohydrochloride
radgocitabine hydrochloride
cndac hcl salt
HY-16445B
cndac (hydrochloride)
EX-A1682
(2r,3s,4s,5r)-2-(4-amino-2-oxopyrimidin-1-yl)-4-hydroxy-5-(hydroxymethyl)oxolane-3-carbonitrile;hydrochloride
cndac hcl
CS-0022139
MS-24125

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" Subsequently, each agent was used in combination with CNDAC at fixed concentration ratios."( Mechanism-Based Drug Combinations with the DNA Strand-Breaking Nucleoside Analog CNDAC.
Hargis, S; Jiang, Y; Liu, X; Nowak, B; Plunkett, W, 2016)		0.43
" Drug combination effects were quantified by median effect analysis."( Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations.
Chen, Y; Cheng, N; Jiang, Y; Liu, X; Nowak, B; Plunkett, W; Qiang, B, 2018)		0.48

Bioavailability

ExcerptReferenceRelevance
"Sapacitabine is an orally bioavailable prodrug of the nucleoside analog 2'-C-cyano-2'-deoxy-1-β-D-arabino-pentofuranosylcytosine (CNDAC)."( Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks.
Liu, XJ; Nowak, B; Plunkett, W; Wang, YQ, 2012)		0.38
"CNDAC (2'-C-cyano-2'-deoxy-1-β-d-arabino-pentofuranosyl-cytosine, DFP10917) and its orally bioavailable prodrug, sapacitabine, are undergoing clinical trials for hematologic malignancies and solid tumors."( Mechanism-Based Drug Combinations with the DNA Strand-Breaking Nucleoside Analog CNDAC.
Hargis, S; Jiang, Y; Liu, X; Nowak, B; Plunkett, W, 2016)		0.43

Dosage Studied

ExcerptRelevanceReference
" However, a clinically available therapeutic regimen for this compound needs to be established and its functional mechanisms in relation to the dosing schedule need to be clarified."( Analysis of the prolonged infusion of DFP-10917, a deoxycytidine analog, as a therapeutic strategy for the treatment of human tumor xenografts in vivo.
Eshima, K; Fukushima, M; Iizuka, K; Jin, C; Zhang, C, 2018)		0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (33)

Assay IDTitleYearJournalArticle
AID137713Percent treated was determined after administration at 400 mg/kg orally1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID201189Tested in vitro against ST-KM human stomach adenocarcinoma1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID135571Percent inhibition against M5076 mouse reticulum cell sarcoma after administration at 300 mg/kg orally on day 201993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID135565Percent inhibition against M5076 mouse reticulum cell sarcoma after administration at 100 mg/kg orally on day 201993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID98505Tested in vitro inhibitory activity against murine leukemia L12101993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID156483Tested in vitro against PC-8 human lung adenocarcinoma1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID136202Tested for 60-day survivors after administration at 100 mg/kg orally in M5076 mouse reticulum cell sarcoma1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID137581Percent treated was determined after administration at 100 mg/kg orally1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID104931Tested in vitro against MNNG/HOS cell line human osteosarcoma1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID136205Tested for 60-day survivors after administration at 200 mg/kg orally in M5076 mouse reticulum cell sarcoma1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID135568Percent inhibition against M5076 mouse reticulum cell sarcoma after administration at 200 mg/kg orally on day 201993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID147784Tested in vitro against OST human osteosarcoma1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID106856Tested in vitro against MKN-45 human stomach adenocarcinoma1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID94681Tested in vitro against KKLS human stomach adenocarcinoma1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID137711Percent treated was determined after administration at 300 mg/kg orally1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID139039Weight change in M5076 mouse reticulum cell sarcoma after administration at 400 mg/kg orally1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID156490Tested in vitro against PC-9 human lung adenocarcinoma1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID8811Tested in vitro against A-375 cell line human melanoma1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID139034Weight change in M5076 mouse reticulum cell sarcoma after administration at 200 mg/kg orally1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID201690Tested in vitro against SW-48 human colon adenocarcinoma1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID163147Tested in vitro against QG-95 human squamous cell carcinoma1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID85582Tested in vitro against HT1080 cell line human fibrosarcoma1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID136345Tested for 60-day survivors after administration at 300 mg/kg orally in M5076 mouse reticulum cell sarcoma1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID139037Weight change in M5076 mouse reticulum cell sarcoma after administration at 300 mg/kg orally1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID101605Tested in vitro against MCF-7 human breast adenocarcinoma1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID135573Percent inhibition against M5076 mouse reticulum cell sarcoma after administration at 400 mg/kg orally on day 201993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID136347Tested for 60-day survivors after administration at 400 mg/kg orally in M5076 mouse reticulum cell sarcoma1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID96383Tested in vitro inhibitory activity against human oral epidermoid carcinoma KB cells1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID137708Percent treated was determined after administration at 200 mg/kg orally1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID139031Weight change in M5076 mouse reticulum cell sarcoma after administration at 100 mg/kg orally1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID95323Tested in vitro against KATO-III human stomach adenocarcinoma1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID219715Tested in vitro against colo-320 human colon adenocarcinoma1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
AID155991Tested in vitro against PC-13 human lung large cell carcinoma1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (29)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's12 (41.38)18.2507
2000's10 (34.48)29.6817
2010's6 (20.69)24.3611
2020's1 (3.45)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (12.90%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other27 (87.10%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
adenine
[no description available]		1.98106-aminopurines;
purine nucleobase		Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
cytosine
[no description available]		3.1450aminopyrimidine;
pyrimidine nucleobase;
pyrimidone		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
thymine
[no description available]		1.9810pyrimidine nucleobase;
pyrimidone		Escherichia coli metabolite;
human metabolite;
mouse metabolite
uracil
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder		1.9810pyrimidine nucleobase;
pyrimidone		allergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prodrug;
Saccharomyces cerevisiae metabolite
dipalmitoylphosphatidic acid
dipalmitoylphosphatidic acid: RN given refers to parent cpd without isomeric designation. dihexadecanoyl phosphatidic acid : A phosphatidic acid in which the phosphatidyl acyl groups are both palmitoyl (hexadecanoyl).		2.0110phosphatidic acid
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		2.3920nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
temozolomide
[no description available]		2.1310imidazotetrazine;
monocarboxylic acid amide;
triazene derivative		alkylating agent;
antineoplastic agent;
prodrug
mitomycin
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.. mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.		210mitomycinalkylating agent;
antineoplastic agent
isoflurophate
Isoflurophate: A di-isopropyl-fluorophosphate which is an irreversible cholinesterase inhibitor used to investigate the NERVOUS SYSTEM.		2.1710dialkyl phosphate
uridine
[no description available]		210uridinesdrug metabolite;
fundamental metabolite;
human metabolite
cytidine
[no description available]		210cytidinesEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
cytarabine
[no description available]		6.33290beta-D-arabinoside;
monosaccharide derivative;
pyrimidine nucleoside		antimetabolite;
antineoplastic agent;
antiviral agent;
immunosuppressive agent
deoxycytidine
[no description available]		4.6280pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
doxifluridine
doxifluridine : A pyrimidine 5'-deoxyribonucleoside that is 5-fluorouridine in which the hydroxy group at the 5' position is replaced by a hydrogen. It is an oral prodrug of the antineoplastic agent 5-fluorouracil. Designed to circumvent the rapid degradation of 5-fluorouracil by dihydropyrimidine dehydrogenase in the gut wall, it is converted into 5-fluorouracil in the presence of pyrimidine nucleoside phosphorylase.		1.9810organofluorine compound;
pyrimidine 5'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
prodrug
platinum
Platinum: A heavy, soft, whitish metal, resembling tin, with atomic number 78, atomic weight 195.084, symbol Pt. It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as alutiae.		2.1310elemental platinum;
nickel group element atom;
platinum group metal atom
camptothecin
NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source		2.1510delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		2.1710taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
gemcitabine
gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.		4.2350organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic
2'-deoxycytidine 5'-triphosphate
2'-deoxycytidine 5'-triphosphate: RN given refers to unlabeled parent cpd		2102'-deoxycytidine phosphate;
pyrimidine 2'-deoxyribonucleoside 5'-triphosphate		Escherichia coli metabolite;
human metabolite;
mouse metabolite
7-hydroxystaurosporine
[no description available]		2.0210
docetaxel anhydrous
Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.		2.0310secondary alpha-hydroxy ketone;
tetracyclic diterpenoid		antimalarial;
antineoplastic agent;
photosensitizing agent
cyc 682
sapacitabine: structure in first source. sapacitabine : A nucleoside analogue resulting from the formal condensation of the carboxy group of hexadecanoic acid with the amino group of CNDAC. It is the prodrug of CNDAC and is currently in clinical development for the treatment of acute myeloid leukemia (AML).		2.9640nitrile;
nucleoside analogue;
secondary carboxamide		antimetabolite;
antineoplastic agent;
DNA synthesis inhibitor;
prodrug
troxacitabine
troxacitabine: shows good anti-HIV activity without cytotoxicity		2.0410carbohydrate derivative;
nucleobase-containing molecular entity
2'-deoxy-2'-methylenecytidine
[no description available]		3.7930
silicon
Silicon: A trace element that constitutes about 27.6% of the earth's crust in the form of SILICON DIOXIDE. It does not occur free in nature. Silicon has the atomic symbol Si, atomic number 14, and atomic weight [28.084; 28.086].		210carbon group element atom;
metalloid atom;
nonmetal atom
selenium
Selenium: An element with the atomic symbol Se, atomic number 34, and atomic weight 78.97. It is an essential micronutrient for mammals and other animals but is toxic in large amounts. Selenium protects intracellular structures against oxidative damage. It is an essential component of GLUTATHIONE PEROXIDASE.		210chalcogen;
nonmetal atom		micronutrient
staurosporine
staurosporinium : Conjugate acid of staurosporine.		2.0210ammonium ion derivative
dacarbazine
(E)-dacarbazine : A dacarbazine in which the N=N double bond adopts a trans-configuration.		2.1310dacarbazine
ConditionIndicatedRelationship StrengthStudiesTrials
Leukemia L 1210
[description not available]		01.9810
Diffuse Large B-Cell Lymphoma
[description not available]		01.9810
Lymphoma, Large B-Cell, Diffuse
Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.		01.9810
Leukemia, Lymphocytic, T Cell
[description not available]		02.2510
Leukemia, T-Cell
A malignant disease of the T-LYMPHOCYTES in the bone marrow, thymus, and/or blood.		02.2510
Colorectal Cancer
[description not available]		02.1510
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		02.1510
Abnormalities, Autosome
[description not available]		02.4720
Cancer of Ovary
[description not available]		02.1710
Ovarian Neoplasms
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.		02.1710
Benign Neoplasms
[description not available]		03.8540
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		03.8540
Acute Myelogenous Leukemia
[description not available]		02.7230
Leukemia, Myeloid, Acute
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.		02.7230
Hematologic Malignancies
[description not available]		02.0210
Hematologic Neoplasms
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.		02.0210
Adenocarcinoma, Basal Cell
[description not available]		01.9810
Cancer of Colon
[description not available]		01.9810
Leukemia P388
An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.		02.940
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		01.9810
Colonic Neoplasms
Tumors or cancer of the COLON.		01.9810
Fibrosarcoma
A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed)		02.420
Necrosis
The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.		02.9110
Cell Transformation, Neoplastic
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.		0210
Experimental Neoplasms
[description not available]		02.6930
Breast Cancer
[description not available]		0210
Cancer of Stomach
[description not available]		0210
Breast Neoplasms
Tumors or cancer of the human BREAST.		0210
Stomach Neoplasms
Tumors or cancer of the STOMACH.		0210
Cancer of Lung
[description not available]		0210
B16 Melanoma
[description not available]		0210
Lung Neoplasms
Tumors or cancer of the LUNG.		0210
Chromosomal Breakage
[description not available]		0210
Malignant Melanoma
[description not available]		0210
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		0210
Angiogenesis, Pathologic
[description not available]		02.0110